Repligen Corporation $RGEN Holdings Decreased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 16.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 70,080 shares of the biotechnology company’s stock after selling 13,700 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Repligen were worth $8,257,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Measured Wealth Private Client Group LLC acquired a new stake in Repligen during the 3rd quarter worth about $29,000. Bayforest Capital Ltd purchased a new position in Repligen during the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen in the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at about $36,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on RGEN shares. Roth Capital began coverage on shares of Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 price target for the company. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. Citigroup upgraded shares of Repligen to a “buy” rating in a research report on Tuesday. Jefferies Financial Group reissued a “hold” rating and set a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Finally, Canaccord Genuity Group lowered their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $165.00.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.60% of the stock is currently owned by company insiders.

Repligen Stock Up 0.2%

Shares of RGEN traded up $0.30 during midday trading on Friday, reaching $144.24. 476,012 shares of the stock were exchanged, compared to its average volume of 997,154. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The firm has a 50 day simple moving average of $126.36 and a 200-day simple moving average of $134.17. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.14 billion, a price-to-earnings ratio of 160.27, a P/E/G ratio of 2.77 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Research analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.